Lipocine announces pro rata distribution of series b preferred stock to its holders of common stock

Salt lake city , march 10, 2023 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that its board of directors declared a dividend of one one-thousandth of a share of newly designated series b preferred stock, par value $0.0001 per share, for each outstanding share of the company's common stock held of record as of 5:00 p.m. eastern time on march 24, 2023.
LPCN Ratings Summary
LPCN Quant Ranking